All relevant data are within the paper and in the Supporting Information files.

Introduction {#sec001}
============

Radical prostatectomy as a primary treatment for clinically localized prostate cancer (PC) has increased dramatically over the past decade due to prostate specific antigen (PSA) screening \[[@pone.0186852.ref001]\]. Despite increased ability to detect cancer, the clinical behavior of PC remains hard to predict as it ranges from indolent to highly aggressive tumors \[[@pone.0186852.ref002]\]. Therefore, new prognostic biomarkers are urgently needed. Management of PC today relies largely on standard clinical factors including Gleason score, prostate specific antigen (PSA) level, clinical stage and measures of tumor extent on biopsy and imaging. These methods, however, have a rather limited potential to stratify indolent from aggressive disease \[[@pone.0186852.ref002]--[@pone.0186852.ref003]\]. After localized radical prostatectomy and radiation therapy, 20--40% of the patients will relapse, progress, and will be in need of androgen deprivation therapies \[[@pone.0186852.ref004]\].

The proliferation marker Ki-67 reflects the tumor cell proliferation rate as it correlates with progression, metastasis and prognosis in a number of different malignancies \[[@pone.0186852.ref005]--[@pone.0186852.ref009]\]. Ki-67 is a nuclear cell cycle-associated regulatory protein and the expression of it can be detected during the interphase in the nucleus of tumor epithelial cells \[[@pone.0186852.ref010]\]. The fact that Ki-67 is involved during all active phases of the cell cycle (G1, S, G2 and mitosis), and absent in resting cells (G0 phase), has made it an excellent marker for determining tumor growth fraction \[[@pone.0186852.ref011]\]. The Ki-67 (MIB-1 antibody) labeling index is the best studied PC marker in needle-biopsies up to date \[[@pone.0186852.ref012]--[@pone.0186852.ref017]\]. Several have found that Ki-67 labeling index shows strong correlation with Gleason score in diagnostic biopsies \[[@pone.0186852.ref012], [@pone.0186852.ref014]\], in subsequent radical prostatectomy \[[@pone.0186852.ref015]--[@pone.0186852.ref017]\], or both \[[@pone.0186852.ref013]\]. Others have found Ki-67 to be a biomarker for disease-free survival \[[@pone.0186852.ref013]\], seminal vesicle invasion and postoperative biochemical recurrence \[[@pone.0186852.ref017]\], and cancer specific death after radical prostatectomy \[[@pone.0186852.ref018]\]. Others have not been able to confirm these results \[[@pone.0186852.ref016]\].

The prognostic value of Ki-67 in PC remains somewhat contradictory and inconclusive mainly due to the biologic tumor heterogeneity, lack of standardization in the immunohistochemical (IHC) assays, quantification methods, cutoff-points used for risk classification, and intra- and inter-observer variability.

The objective of this large multicenter study with long follow-up was to investigate if Ki-67 may provide additional information to prognostic indicators in PC. A cohort of 535 PC patients, treated with radical prostatectomies but without pre-operative hormonal therapy was investigated.

Materials and methods {#sec002}
=====================

Patients and tissue microarray {#sec003}
------------------------------

671 patients with radical prostatectomies (RPs) diagnosed with adenocarcinoma of the prostate were retrospectively identified. The samples were collected between 01.01.1995 to 31.12.2005 from the archives of the Departments of Clinical Pathology at the University Hospital of North Norway, St. Olav Hospital and Nordland Hospital. Of these, 136 patients were excluded due to other cancer within five years of PC diagnosis, radiotherapy to the pelvis prior to surgery, inadequate paraffin-embedded tissue blocks and missing follow-up data. None of the patients received a preoperative hormonal therapy. Included in the study was a total of 535 patients with complete follow-up data and available PC tissue. Median follow-up was 12.4 years (range 1.5--20 years). The most recent follow-up was December 2015. Biochemical failure (BF) was defined as postoperative PSA ≥ 0.4ng/ml and rising in a minimum of two different blood samples. Biochemical failure-free survival (BFFS) was calculated as time from surgery to last follow up (FU) date, or date with PSA above threshold (≥ 0.4 ng/ml in a minimum of two different blood samples postoperatively). Clinical failure-free survival (CFFS) was defined as verified, symptomatic, locally advanced progression after radical treatments or metastasis to bone, visceral organs or lymph nodes verified by radiology. Prostate cancer death free survival (PCDFS), was defined as death caused by PC stated in the patient's journal. Further information regarding patients\' data, exclusion criteria, definitions of variables and endpoints, has been previously published \[[@pone.0186852.ref019]\]. All primary cancers were histologically reviewed by two pathologists (ER and LTB) and the tumors were graded according to the recent Gleason grading system; *The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma* \[[@pone.0186852.ref020]\] and staged according to the new guidelines \[[@pone.0186852.ref021]\].

The current study was approved by the ethics committee, REK Nord (2009/1393), including a mandatory re-application January 22. 2016, and the Data Protection Official for Research. The National Data Inspection Board have approved the study. The ethics committee waived the need for patients consent in this retrospective study. The patient records were anonymized prior the research. The reporting of clinicopathological variables, survival data and biomarker expressions was conducted in accordance with the REMARK guidelines \[[@pone.0186852.ref022]\].

Microarray construction {#sec004}
-----------------------

We used tissue microarrays (TMA) and twelve TMA blocks were constructed. A tissue-arraying instrument (Beecher Instruments, Silver Springs, MD, USA) was used for this purpose. We collected formalin-fixed paraffin-embedded (FFPE) tissue blocks from included patients. The author (ER) identified two different areas of tumor compartment (tumor epithelial cells) and two areas of tumor surrounding microenvironment. Two areas of normal epithelial cells and normal stromal tissue was also sampled as controls. Cores with a diameter of 0.6 mm from donor block was collected and inserted into recipient TMA blocks. Multiple 4 μm sections were cut with a Micron microtome (HM355S), affixed to glass slides, and sealed with paraffin. The detailed methodology has been reported previously \[[@pone.0186852.ref023]\].

Immunohistochemistry (IHC) and quantification of Ki67 immunostaining {#sec005}
--------------------------------------------------------------------

The following antibody from Ventana Medical Systems (Tucson, Arizona, USA) was applied to assess the proliferative activity of normal and neoplastic tissues: CONFIRM Ki-67 (clone, 30--9), a rabbit monoclonal primary antibody directed against the C-terminal portion of the Ki-67 antigen. The applied antibody is used in routine diagnostic IHC and has FDA approval (510k) for IVD (*in vitro* diagnostic) use. Ki-67 positive staining was identified by the presence of brown nuclear (DAB) staining in tumor cells. Ki-67 index was quantified using The ARIOL imaging system (Applied Imaging Corp., San Jose, CA, USA) and light microscope. The ARIOL imaging system consisted of a microscope (Olympus BX 61), an automatic stage, slide loader and a camera. All cores were photographed at 20x magnification and the images was semi-quantitatively scored. For both methods, the ARIOL imaging system and the light microscope, the percentage of positive nuclear stained tumor cells among total number of at least 200 tumor cells were counted for each core and scored according to the following system: 0 = 0%, 1 = 1--2.5%, 2 = 2.6--4, 3 ≥ 5%. For both methods, the scoring values were then dichotomized as high or low expression separated by mean value. A high expression was defined as scoring values ≥ 1.43 (visual scoring using light microscope) and ≥ 1.34 (digital scoring).

Statistical methods {#sec006}
-------------------

All statistical analyses were performed using the statistical package IBM SPSS, version 24 (SPSS Inc., Chicago, IL, USA). Spearman correlation coefficient was used to examine the association between Ki-67 score and clinicopathological variables. The Kaplan-Meier method was used for the univariate survival analysis, and log-rank test was used to assess statistical significance. Univariate analyses were performed for the following end-points: biochemical failure (BF), clinical failure (CF) and death of prostate cancer (PCD). All significant variables from the univariate analyses were entered into the multivariate model using backward stepwise Cox regression model with a probability for stepwise entry and removal at 0.05 and 0.1, respectively. The IHC scoring values from each pathologist were compared for inter-observer reliability by use of a two-way random effect model with absolute agreement definition. The significance level used was p \< 0.05 for all analyses.

Results {#sec007}
=======

Patient characteristics {#sec008}
-----------------------

Overview of the patient's characteristics' is presented in [Table 1](#pone.0186852.t001){ref-type="table"} and [S1 Table](#pone.0186852.s001){ref-type="supplementary-material"}. Median age at surgery was 62 years (47 to 76). The surgical procedures were retropubic in 435 cases (81%) and perineal in 100 cases (19%). Gleason grade group ranged from 1 to 5 (updated Gleason grade system); 1 (≤ 6), 2 (3+4), 3 (4+3), 4 (4+4) and 5 (≥ 8). Tumor stage ranged from T2a to T3b. Median PSA was 8.8 (range 0.7--104). At the last follow-up, 200 (37%) had BF, 56 (11%) had experienced CF and 18 (3.4%) had died of PC.

10.1371/journal.pone.0186852.t001

###### Patient characteristics clinicopathological variables and their prognostic variables for BF, CF and PCD (univariate analysis; log-rank test) (N = 535).

![](pone.0186852.t001){#pone.0186852.t001g}

  -------------------------------------------------------------------------------------------------------------------------------
  Characteristic              Patients\   Patients\   BF\            CF\           PCD\                             
                              (n)         (%)         (200 events)   (56 events)   (18 events)                      
  --------------------------- ----------- ----------- -------------- ------------- ------------- ------------- ---- -------------
  **Age**                                                            0.237                       **0.038**          0.600

      ≤ 65 years              357         67          76                           92                          97   

      \> 65 years             178         33          70                           88                          96   

  **pT-stage**                                                       **\<0.001**                 **\<0.001**        **0.027**

      pT2                     374         70          83                           97                          98   

      pT3a                    114         21          61                           87                          98   

      pT3b                    47          9           43                           73                          89   

  **Preoperative PSA**                                               **\<0.001**                 0.029              0.061

      PSA\<10                 308         57          81                           95                          99   

      PSA\>10                 221         42          68                           89                          95   

      Missing                 6           1           \-                           \-                          \-   

  **ISUP grade group**                                               **\<0.001**                 **\<0.001**        **\<0.001**

      1 (3+3)                 183         34          83                           98                          99   

      2 (3+4)                 219         41          77                           94                          98   

      3 (4+3)                 81          15          70                           90                          95   

      4 (4+4)                 17          4           58                           86                          94   

      5 (\>8)                 35          6           37                           65                          87   

  **Tumor Size**                                                     **\<0.001**                 **0.019**          0.098

      0--20 mm                250         47          83                           94                          99   

      \>20 mm                 285         53          68                           88                          96   

  **PNI**                                                            **\<0.001**                 **\<0.001**        **0.002**

      No                      401         75          80                           96                          98   

      Yes                     134         25          60                           83                          93   

  **PSM**                                                            **0.049**                   **0.198**          0.697

      No                      249         47          81                           96                          97   

      Yes                     286         53          69                           90                          97   

  **Non-apical PSM**                                                 **\<0.001**                 **\<0.001**        **0.029**

      No                      381         71          82                           96                          98   

      Yes                     154         29          57                           85                          94   

  **Apical PSM**                                                     0.063                       0.427              0.313

      No                      325         61          74                           90                          96   

      Yes                     210         39          77                           92                          98   

  **Vascular infiltration**                                          **\<0.001**                 **\<0.001**        **0.009**

      No                      492         92          77                           95                          98   

      Yes                     43          8           47                           69                          88   

  **Nstage**                                                         **\<0.001**                 **\<0.001**        **\<0.001**

      Nx                      264         49          79                           96                          99   

      N0                      268         50          72                           90                          97   

      N1                      3           1           0                            33                          67   
  -------------------------------------------------------------------------------------------------------------------------------

Abbreviations: BF = biochemical failure; CF = clinical failure; EFS = event free survival in months; PCD = prostate cancer death; p = p value for log rank statistics for difference in event free survival; PC = prostate cancer; PNI = perineural infiltration; PSA = prostate specific antigen; PSM = positive surgical margin; Nstage = nodal status

Ki67 expression and correlations with clinicopathological variables {#sec009}
-------------------------------------------------------------------

Nuclear staining of Ki-67 in tumor epithelial cells was observed. The intensity of the nuclear staining was varying from negative, weak, to moderate and strong, and all grades, except negative results, were regarded as positive cells ([Fig 1](#pone.0186852.g001){ref-type="fig"}). Ki-67 nuclear staining was evaluated by using light microscope (visual scoring) and digital image analysis. Two experienced pathologists independently scored the TMA-slides without any prior knowledge of the patients' clinicopathological data or any clinical end-points. Positive Ki-67 staining was clearly detected in the nucleus of tumor epithelial cells, in 452 (84%) of the total of 535 patients (visual scoring) and in 483 (90%), digital scoring method. Of those with detected staining, 61% had a low Ki-67 expression (\< 1.43) and 39% had a high expression (≥ 1.43). Using cutoff-value \< 1.34 and ≥ 1.34, 60% had low expression and 40% a high expression, respectively ([Fig 1A--1F](#pone.0186852.g001){ref-type="fig"}). Interobserver scoring agreement (ICC), for Ki-67 expression in tumor epithelial cells was: ICC = 0.78 (CI: 0.74--0.82, p \< 0.001). When stratifying the analyses by the different surgical centres, the results remained unchanged. ([S1 Fig](#pone.0186852.s002){ref-type="supplementary-material"})

![Representative immunohistochemical staining for Ki-67.\
**(A)** Gleason grade group 1 (3+3) with Ki-67 \<1--2.5%; **(B)** Gleason grade group 3 (4+3) with Ki-67 \<1--2.5%; **(C)** Gleason grade group 3 (4+3) with Ki-67 2.6--4%; **(D)** Gleason grade group 4 (4+4) with Ki-67 ≥ 5; **(E)** Gleason grade group 5 (4--5) with Ki-67 2.6--4; **(F)** Picture showing the different Ki-67 expression of nuclear staining, varying from negative to strong.](pone.0186852.g001){#pone.0186852.g001}

The correlation between Ki-67 level and clinicopathological variables was generally weak or non-significant (r \< 0.2). However, positive correlations were found between high Ki-67 expression and Gleason grade ≥8 (p = 0.001), tumor size ≥ 20 millimeter (p = 0.03) and pT-Stage T3b (p = 0.053).

We also correlated Ki-67 expression with previous investigated markers \[[@pone.0186852.ref024]--[@pone.0186852.ref027]\], but no significant correlation was found.

### Univariate analyses {#sec010}

Significant variables, for the endpoints BF, CF and PCD are all presented in [Table 1](#pone.0186852.t001){ref-type="table"}. For BF, significant prognostic factors were: pT-stage (p \< 0.001), preoperative PSA (p \< 0.001), Gleason score (p \< 0.001), tumor size (p \< 0.001), perineural infiltration (PNI, p \< 0.001), non-apical PSM (p  =  0.049), apical PSM (p \< 0.001), vascular infiltration (p \< 0.001), and pN-stage (p \< 0.001). For CF, significant prognostic factors were: pT-stage (p \< 0.001), Gleason score (p \< 0.001), tumor size (p  =  0.019), PNI (p  =  0.001), non-apical PSM (p \< 0.001), vascular infiltration (p \< 0.001) and pN-stage (p \< 0.001). For PCD the significant prognostic factors were: pT-stage (p  =  0.027), Gleason score (p \< 0.001), PNI (p  =  0.002), non-apical PSM (p  =  0.029), vascular infiltration (p  =  0.009) and pN-stage (p \< 0.001). A high Ki-67 expression (≥ 1.34) in tumor epithelium (digital scoring method) was significantly associated with BF, (p = 0.014, [Fig 2A](#pone.0186852.g002){ref-type="fig"}), but not with CF (p = 0.405) or PCD (p = 0.752). For visual scoring with high cut-off value ≥ 1.43, high Ki-67 expression was significant with BF (p = 0.04), but not with CF (p = 0.129) or PCD (p = 0.502). Stratification of the cohort into prognostic groups according to the American Joint Committee on Cancer (AJCC) TNM system was implemented \[[@pone.0186852.ref028]\]. Neither high- or low levels of Ki-67 was significant for any the staging groups; I (n = 43), IIA (n = 111), IIB (219), III (n = 219) or IV (n = 3).

![Survival analysis for Ki-67 and mitotic count in primary tumors.\
(Kaplan-Meier method). Number of events/number of cases are given in parenthesis. **(A)** Digital scoring; **(B)** Visual scoring.](pone.0186852.g002){#pone.0186852.g002}

### Multivariate analyses {#sec011}

Results from the multivariate analysis are represented in [Table 2](#pone.0186852.t002){ref-type="table"} (digital scoring): pT-stage (p = 0.003), pT3a (p = 0.001, HR: 0.44, CI95% 0.27--0.82), ISUP grade group 2 (p = 0.028, HR: 0.52, CI95% 0.30--0.93), PNI (p = 0.040, HR: 1.70, CI95% 0.50--0.98) and non-apical PSM (p = 0.002, HR: 0.60, CI95% 0.43--0.83) were independent prognostic factors for BF. For CF, ISUP grade group 3 (p \< 0.000), ISUP grade group 2 (\< 0.000, HR: 0.08, CI95% 0.03--0.23); ISUP grade group 3 (p = 0.001, HR: 0.28 CI95% 0.13--0.58), ISUP grade group 4 (p = 0.022, HR: 0.38 CI95% 0.17--0.87) and non-apical PSM (p = 0.041, HR: 0.60, CI95% 0.54--0.97). For PCD, ISUP grade group 2 (p = 0.033, HR: 0.11, CI95% 0.03--0.86), ISUP grade group 3 (p = 0.035, HR:0.19, CI95% 0.04--0.89) and PNI (p = 0.027, HR: 0.30, CI95% 0.11--0.89--9). Ki-67 was not significant with none of the endpoints. Visual scoring is presented in [Table 3](#pone.0186852.t003){ref-type="table"}. For BF, pT-stage (p \< 0.002), pT3a (p \< 0.000, HR: 0.42, CI95% 0.26--0.69), pT3b (p = 0.047, HR: 0.62, CI95% 0.39--0.99), preoperative PSA \> 10ng/ml (p = 0.046, HR: 0.68, CI95% 0.49--0.94), PNI (p \< 0.008, HR: 0.62, CI95% 0.44--0.88), non-apical PSM (p \< 0.000, HR: 0.54, CI95% 0.39--0.77), apical PSM (p = 0.043, HR: 1.42, CI95% 1.01--2.00) and Ki67 (p = 0.012, HR: 1.50, CI95% 1.10--2.06). For CF, ISUP grade group (p \< 0.000), grade group 2 (p \< 0.000, HR: 0.07, CI95% 0.02--0.21), ISUP grade group 3 (p \< 0.000, HR: 0.25, CI95% 0.12--0.51), ISUP grade group 4 (p = 0.015, HR: 0.34, CI95% 0.15--1.30), non-apical PSM (p = 0.007, HR: 0.45, CI95% 0.30--1.10). For PCD, PSA \> 10ng/ml (p = 0.034, HR: 0.25, CI95% 0.07--0.90), ISUP grade group 2 (p = 0.047, HR: 0.17, CI95% 0.07--0.90) and ISUP grade group 3 (p = 0.035, HR: 0.20, CI95% 0.04--0.91). Ki-67 was not significant with endpoints CF or PCD.

10.1371/journal.pone.0186852.t002

###### Multivariate analyses (Cox regression, backward conditional) of Ki67 levels and significant clinicopathological variables.

(n = 535). Digital scoring method.

![](pone.0186852.t002){#pone.0186852.t002g}

  ---------------------------------------------------------------------------------------------------------------------
  Characteristic              No    BF (200 events)\            CF (56 events)\             PCD (18 events)\
                                    HR CI95% p                  HR CI95% p                  HR CI95% p
  --------------------------- ----- --------------------------- --------------------------- ---------------------------
  **Age**                           NS                          NS                          NS

    ≤ 65 years                321                                                           

    \> 65 years               65                                                            

  **pT-stage**                      **0.003**                   NS                          NS

    pT2                       333   1                                                       

    pT3a                      102   0.44 0.27--0.82 **0.003**                               

    pT3b                      40    0.70 0.44--1.12 0.140                                   

  **Preoperative PSA**              NS                          NS                          NS

    PSA \<10                  278                                                           

    PSA \>10                  200                                                           

  **ISUP grade group**              0.063                       **0.000**                   0.095

    1 (3+3)                   157   1                           1                           1

    2 (3+4)                   198   0.52 0.30--0.93 **0.028**   0.08 0.03--0.23 **0.000**   0.11 0.03--0.86 **0.033**

    3 (4+3)                   74    0.62 0.35--1.08 0.091       0.28 0.13--0.58 **0.001**   0.19 0.04--0.89 **0.035**

    4 (4+4)                   17    0.87 0.48--1.56 0.633       0.38 0.17--0.87 **0.022**   0.79 0.25--2.65 0.700

    5 (\>8)                   32    1.02 0.46--2.26 0.956       0.44 0.12--1.54 0.199       0.61 0.07--5.31 0.651

  **Tumor size**                    NS                          NS                          NS

    0--20 mm                  215                                                           

    \>20 mm                   263                                                           

  **PNI**                           **0.040**                   NS                          **0.027**

    No                        401   1                           1                           

    Yes                       134   0.70 0.50--0.98             0.30 0.11--0.87             

  **Non-apical PSM**                **0.002**                   **0.041**                   NS\

    No                        381   1                           1                           

    Yes                       154   0.60 0.43--0.83             0.54 0.30--0.97             

  **Apical PSM**                    NS                          NS                          NS

    No                        325                                                           

    Yes                       210                                                           

  **Vascular infiltration**         NS                          NS                          NS

    No                        437                                                           

    Yes                       41                                                            

  **Ki67 level**                    NS                          NS                          NS

    Low                       289                                                           

    High                      189                                                           
  ---------------------------------------------------------------------------------------------------------------------

Abbreviations: BF = biochemical failure; CF = clinical failure; PSA = prostate specific antigen; PNI = perineural infiltration, PSM = positive surgical margin; NS = not significant.

10.1371/journal.pone.0186852.t003

###### Multivariate analyses (Cox regression, backward conditional) of Ki67 levels and significant clinicopathological variables.

(n = 535). Visual scoring method.

![](pone.0186852.t003){#pone.0186852.t003g}

  ---------------------------------------------------------------------------------------------------------------------
  Characteristic              No    BF (200 events)\            CF (56 events)\             PCD (18 events)\
                                    HR CI95% p                  HR CI95% p                  HR CI95% p
  --------------------------- ----- --------------------------- --------------------------- ---------------------------
  **Age**                           NS                          NS                          NS

    ≤ 65 years                299                                                           

    \> 65 years               148                                                           

  **pT-stage**                      **0.002**                   NS                          0.090

    pT2                       307   1                           1                           

    pT3a                      102   0.42 0.26--0.69 **0.001**   0.07 0.01--0.79 **0.031**   

    pT3b                      38    0.62 0.39--0.99 **0.047**   0.11 0.01--0.96 **0.046**   

  **Preoperative PSA**              **0.046**                   NS                          **0.034**

    PSA \<10                  255   1                           1                           

    PSA \>10                  192   0.62 0.49--0.94             0.25 0.07--0.90             

  **ISUP grade group**              0.077                       **0.000**                   0.161

    1 (3+3)                   139   1                           1                           1

    2 (3+4)                   190   0.00 0.00--0.47 **0.023**   0.07 0.02--0.21 **0.000**   0.17 0.03--0.98 **0.047**

    3 (4+3)                   71    0.02 0.00--0.54 **0.020**   0.25 0.12--0.51 **0.000**   0.13 0.04--0.91 **0.037**

    4 (4+4)                   16    0.03 0.00--0.78 **0.035**   0.34 0.15--1.30 **0.015**   0.66 0.18--2.33 0.513

    5 (≥9)                    31    0.18 0.23--1.11 0.065       0.37 0.11--1.30 **0.121**   0.59 0.07--5.17 0.631

  **Tumor size**                    NS                          NS                          NS

    0--20 mm                  192                                                           

    \>20 mm                   255                                                           

  **PNI**                           **0.008**                   NS                          **0.005**

    No                        332   1                           1                           

    Yes                       115   0.62 0.44--0.88             0.19 0.05--0.66             

  **Non-apical PSM**                **0.000**                   **0.007**                   

    No                        313   1                           1                           

    Yes                       134   0.54 0.39--0.77             0.45 0.30--1.10             

  **Apical PSM**                    **0.034**                   NS                          NS

    No                        274   1                                                       

    Yes                       173   1.42 1.01--2.00                                         

  **Vascular infiltration**         NS                          NS                          NS

    No                        408                                                           

    Yes                       39                                                            

  **Ki67 level**                    **0.012**                   NS\                         NS
                                                                1                           

    Low                       257   1                                                       

    High                      175   1.50 1.10--1.26                                         
  ---------------------------------------------------------------------------------------------------------------------

**Abbreviations:** BF = biochemical failure; CF = clinical failure; PSA = prostate specific antigen; PNI = perineural infiltration, PSM = positive surgical margin; NS = not significant.

Discussion {#sec012}
==========

Uncontrolled proliferation is a hallmark of malignancy and the measurement of Ki-67 antigen by using IHC is the most widely performed assessment of a tumor's proliferation potential. In this large-scale multi-center study with long-term survival data, we found that a high expression of Ki-67 was an independent predictor for biochemical failure (both scoring methods). By using visual scorings method, a high Ki-67 was found as an independent predictor for BF in multivariate analyses. High expression of Ki-67 was strongly correlated to Gleason grade ≥ 8 and increased tumor size (\> 20 mm). To the best of our knowledge, our study is one of the largest series to explore the prognostic impact of mitotic count by using two different methods.

Counting of mitoses is the classical method used to determine proliferative activity in normal and neoplastic tissues by using light microscopy. Despite that a lot of previous studies have confirmed Ki-67 as a prognostic factor for PC \[[@pone.0186852.ref012]--[@pone.0186852.ref018], [@pone.0186852.ref029]--[@pone.0186852.ref031]\], Ki-67 count has not been implemented in PC is not implemented in PC diagnosis. One of the main reason for this, includes, the morphologic heterogeneity of PC, as these methods only registers the M phase of the cell cycle \[[@pone.0186852.ref002]--[@pone.0186852.ref003]\] while, the number of identifiable mitoses may also depend upon the period of time between surgical removal and fixation of the specimen \[[@pone.0186852.ref032]\], Furthermore, there are several available antibodies or Ki-67 IHC staining, but there is no standard operating protocol, and the cut-off definition values for Ki-67 levels have not been established \[[@pone.0186852.ref033]\]. Moreover, the biological heterogeneity of Ki67 staining can occur across prostate cancer specimens, and definition of the location and extent of the area of the cancer that should be scored is controversial needs to be more clearly defined. This has the main important reason of the low interobserver reproducibility. Importantly, most studies are retrospectively designed with various number of patients included \[[@pone.0186852.ref012]--[@pone.0186852.ref018]\] which may explain the poor reproducibility of mitotic counts.

However, a significant association have been found between Ki-67 antigen expression and time to progression, high Gleason grade, large tumor size, metastasis, mortality and to predict distant metastases in men treated with radiotherapy and androgen deprivation \[[@pone.0186852.ref012], [@pone.0186852.ref013], [@pone.0186852.ref017], [@pone.0186852.ref018], [@pone.0186852.ref029]--[@pone.0186852.ref031], [@pone.0186852.ref034]\]. We did not find any association between Ki-67 and CF and PCD. This is most likely due with the low number of events for CF and PCD in our cohort. In two published PC studies measuring proliferating by using MIB-1 the investigators were not able to find significant association with PC and Ki-67 expression \[[@pone.0186852.ref015], [@pone.0186852.ref016]\].

Immunostaining for Ki-67 (IHC), is relatively straightforward. By means of immunostaining it is possible to assess the growth fraction of neoplastic cell populations. In this study, we used the anti-Ki-67 (clone:30--9) antibody which is a rabbit monoclonal primary antibody from Ventana. This antibody is intended for use to identify stained proliferating cells by light microscopy in sections of formalin fixed, paraffin embedded tissue. However, in practice, the monoclonal antibody MIB-1 is probably the most widely used proliferative marker. It reacts with an antigen that is only present in the nucleus of proliferating cells and has similar epitope sensitivity to Ki-67. There have been many reports of correlations between Ki-67 equivalent antibodies and other proliferation markers \[[@pone.0186852.ref035], [@pone.0186852.ref036]\]. The antibody used in this study is in daily use in our pathology department to assess the proliferative activity of normal and neoplastic cells. A study by Leonardo et al. \[[@pone.0186852.ref037]\] concluded that as a rabbit monoclonal antibody (RbMAb), it demonstrates increased sensitivity and strong specificity compared with mouse monoclonal antibodies (MMAbs). With intense nuclear staining and no adipose (K2) or cell membrane staining (MIB-1), CONFIRM Ki-67 (30--9) rabbit monoclonal antibody can be used in assessment of tumor aggressiveness \[[@pone.0186852.ref037]\].

Determination of proliferative activity by the use of Ki-67 depends on several factors, the most obvious being the interobserver variation. In our study, we used the same cut-off values and TMA-slides for both visual and digital analyses, and observed, in fact, a good ICC between the two investigators. At the other hand, the interpretation is not straightforward.

In the present study, we used two different approaches to measure Ki-67 expression, by visual and digital scoring. There was high inter-correlation agreement between the pathologist visual scoring and the pathologist digital scoring. This is in agreement with one similar study (no = 225) \[[@pone.0186852.ref037]\]. Limitations of our study include its retrospective nature as well as the use of TMA cores and not whole slide sections to determine the proliferative activity. Although the use of TMA may result in a bias, due to the heterogeneity of PC. A more representative method, at least with respect to Ki-67, could be better achieved with multiple cores taken from each single lesion. Another limitation might be the antibody used. Nevertheless, international standardisation of analysis and assessment of any potential biomarker is an important aspect for a successful translation into the routine setting \[[@pone.0186852.ref038]\].

In conclusion, Ki-67 is a biomarker for tumor cell proliferation. In our study, we found that a high Ki-67 expression was an independent prognostic marker for biochemical failure, high Gleason grade and larger tumor size. Despite unresolved issues on Ki-67 value cut-offs, we suggest that the analysis of Ki-67 add information regarding the aggressiveness of prostate tumors.
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